

Clinical Trials at Gold Coast Health

Current as of 10 July 2018

Please email or call the lead contact to get in touch with the Principal Investigator for a specific trial.



IMPACT Trial Intensive Care, 2018

Contents

Allied Health	3
Occupational Therapy	3
Speech Pathology	3
Physiotherapy	4
Cancer	5
Haematology	5
Oncology	9
Radiation Oncology	14
Complementary medicines	16
Emergency medicine	17
Intensive Care	18
Medical Specialities and Medical Imaging	22
Cardiology	22
Endocrinology	25
Interventional Neuroradiology	26
Neurology	27
Renal	31
Psychiatry	31
Surgery	33
Breast Surgery	33
ENT Surgery	34
Orthopaedic Surgery	34
Colorectal Surgery	35
Anaesthetics	35
Endoscopy	36
Trauma	36
Women, Children and Newborns	38
Obstetrics and Gynaecology	38
Paediatrics and Neonates	38

This list is updated every 6 months, in July and January.

Allied Health

Occupational Therapy

We focus on improving patients' health and well-being, so they can participate in daily life occupations.

SMART trial

Enrolling eligible inpatients

This trial implements SMART Arm training to promote arm and hand recovery early after stroke at the Gold Coast University Hospital (GCUH).

Read more [about trial](#).

SSA/16/QGC/64

Lead Contact: Ms Ashlea Walker

Phone: (07) 5687 3324

Email: Ashlea.Walker@health.qld.gov.au

Speech Pathology

We treat people with communication disorders such as those with their verbal and written communication; and their reading, and listening.

COMPARE trial

Active, recruiting patients

This is a randomised controlled trial for stroke related chronic aphasia.

Read more [about trial](#).

SSA/15/QGC/316

Principal Investigator: Ms Melissa Lawrie

Lead Contact: Ms Rachel Wenke

Phone: (07) 5687 3041

Email: Rachel.Wenke@health.qld.gov.au

Be Clear Online trial

Active, recruiting patients

This is an intensive speech treatment for adults with non-progressive dysarthria.

Read more [about trial](#).

SSA/17/QGC/83

Lead Contact: Ms Rachel Wenke

Phone: (07) 5687 3041

Email: Rachel.Wenke@health.qld.gov.au

SOFTT trial

Active, recruiting patients

This trial investigates teats to support Successful transition to Oral Feeding (SOFTT) in preterm and fragile infants.

Read more [about trial](#).

SSA/17/QGC/109

Principal Investigator: Ms Angie Canning

Lead Contact: Ms Rachael Oorloff

Phone: (07) 5687 3176

Email: Rachael.Oorloff@health.qld.gov.au

Physiotherapy

We help improve and prevent various movement disorders such as painful or stiff joints and mobility difficulties.

CHESTY trial

Enrolling inpatients

A trial investigating the incidence of respiratory complications in adults following major surgery.

Read more [about trial](#).

SSA/18/QGC/53

Lead Contact: Ms Lauren O'Connor

Phone: (07) 5687 5724

Email: Lauren.oconnor@health.qld.gov.au

Cancer

Haematology

We treat cancers that are related to blood or blood-forming organs.

ALLG NHL29 trial

Active, recruiting patients

This Phase 2 trial assesses the effects of ibrutinib when given with rituximab in very elderly patients diagnosed with diffuse large b-cell lymphoma.

Read more [about trial](#).

SSA/15/QGC/251

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

VENICE II trial

Active, participant follow-up only

This Phase 3 trial evaluates the use of venetoclax as the main therapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).

Read more [about trial](#).

SSA/16/QGC/340

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

GOSSAMER trial

Active, recruiting patients

A Phase 3 trial assessing ASP2215 (gilteritinib) versus placebo after the completion of chemotherapy in patients with FMS-like tyrosine kinase 3 (FLT3) or internal tandem duplication (ITD) acute myeloid leukemia (AML) to compare the rates of relapse-free survival (RFS).

Read more [about trial](#).

SSA/17/QGC/92

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

ACE-LY-308 trial

Active, recruiting patients

This Phase 3 study evaluates the efficacy of acalabrutinib with bendamustine and rituximab (BR) compared to placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Read more [about trial](#).

SSA/17/QGC/136

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

BOSTON trial

Active, recruiting patients

This Phase 3 trial compares the safety, efficacy and health-related quality of life of selinexor plus bortezomib (Velcade®) and low-dose dexamethasone versus bortezomib plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) who have received prior anti-multiple myeloma regimens.

Read more [about trial](#).

SSA/17/QGC/353

Principal Investigator: Dr Michelle Bryson

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

VCDD in transplant ineligible myeloma trial

Active, recruiting patients

This is a Phase 2 trial of bortezomib, cyclophosphamide, and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.

Read more [about trial](#).

SSA/18/QGC/2

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

M16-183 trial

Active, recruiting patients

This Phase 1 trial assesses the safety, pharmacokinetics, efficacy and the recommended co-administered therapy doses of dinaciclib and venetoclax for patients with relapsed or refractory acute myeloid leukemia.

Read more [about trial](#).

HREC/18/QGC/166

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

POLLUX trial

Active, participant follow-up only

This Phase 3 trial compares the effectiveness of daratumumab with lenalidomide and dexamethasone to lenalidomide and dexamethasone only, in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Read more [about trial](#).

SSA/14/QGC/189

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

LaRDR trial

Active, recruiting patients

This is a lymphoma and related diseases registry that is an Australasian initiative to improve the treatment and outcomes of patients with lymphoma.

Read more [about trial](#).

SSA/18/QGC/8

Principal Investigator: Dr Tara Cochrane

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

Oncology

We treat cancers either through radiotherapy, surgery to remove tumours, or chemotherapy (or other medicines).

MK-3475-054/KEYNOTE-054 trial

Active, participant follow-up only

This Phase 3 study assesses whether post-resection adjuvant therapy with pembrolizumab improves recurrence-free survival (RFS) compared to placebo for high-risk patients with Stage IIIA, IIIB, or IIIC melanoma.

Read more [about trial](#).

SSA/15/QGC/285

Principal Investigator: Dr Martin Dzienis

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

JAVELIN Lung 100 trial

Active, participant follow-up only

This Phase 3 study determines the clinical benefit (overall survival) of first line treatment avelumab versus platinum-based doublet in patients with advanced non-small lung cancer (NSCLC).

Read more [about trial](#).

SSA/16/QGC/120

Principal Investigator: Dr Jasotha Sanmugarajah

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

CanStem303C trial

Active, recruiting patients

This Phase 3 study reviews treatment regimens of napabucasin plus standard bi-weekly FOLFIRI (5-Fluorouracil, Leucovorin, Irinotecan) versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal Cancer (CRC).

Read more [about trial](#).

SSA/17/QGC/35

Principal Investigator: Dr Marco Matos & Dr Wade Pullin

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

MonarchE trial

Active, recruiting patients

This Phase 3 trial evaluates the safety and efficacy of study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Read more [about trial](#).

SSA/17/QGC/224

Principal Investigator: Dr Jasotha Sanmugarajah

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

BR.34 trial

Active, recruiting patients

This is a Phase 2 trial of new immunotherapy drugs called durvalumab and tremelimumab with chemotherapy in patients with high-risk, metastatic (stage IV), squamous or non-squamous, non-small cell lung cancer (NSCLC).

Read more [about trial](#).

SSA/18/QGC/57

Principal Investigator: Dr Jasotha Sanmugarajah

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

MONARCC trial

Active, recruiting patients

This Phase 2 trial investigates the activity of anti-EGFR (anti-epidermal growth factor) monotherapy, or combined with chemotherapy, in elderly patients with metastatic colorectal cancer.

Read more [about trial](#).

SSA/18/QGC/63

Principal Investigator: Dr Susan Caird

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

DINAMIC trial

Enrolling inpatients

This trial evaluates current methods for the effective decontamination of needleless connectors in adult patients requiring central venous access devices.

Read more [about trial](#).

SSA/18/QGC/172

Principal Investigator: Ms Julie Flynn

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

HLX20-001 trial

Active, recruiting patients

This Phase 1 trial determines the maximum tolerated dose and recommended dose of humanized anti-PD-1 monoclonal antibody, HLX10, in patients with advanced or metastatic tumors resistant to standard therapy.

Read more [about trial](#).

HREC/18/QGC/85

Principal Investigator: Dr Jasotha Sanmugarajah

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

ILLUMINATE-301 trial

Active, recruiting patients

This is a Phase 3 trial for patients with advanced melanoma to determine if the new immunotherapy drug, IMO-2125, with or without ipilimumab extends survival compared to ipilimumab alone.

Read more [about trial](#).

SSA/18/QGC/173

Principal Investigator: Dr Marcin Dzienis

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

ENZAMET trial

Active, participant follow-up only

A Phase 3 trial of male participants with metastatic prostate cancer in treatment with a luteinising hormone releasing hormone analogue (LHRHA); or surgical castration combined with either daily Enzalutamide or conventional Non-steroidal anti-androgen (NSAA) to determine overall survival.

Read more [about trial](#).

SSA/14/QGC/68

Principal Investigator: Dr Suzanne Allan

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

TRACC trial

Active, recruiting patients

This is a study of the clinical outcomes from using Bevacizumab (Avastin®) as a first-line treatment for patients with metastatic colorectal cancer.

Read more [about trial](#).

SSA/17/QGC/310

Principal Investigator: Dr Susan Caird

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

BREAKOUT trial

Active, recruiting patients

This study estimates the prevalence of germline breast susceptibility gene (gBRCA) mutations among metastatic HER2-ve patients who have commenced 1st line systemic cytotoxic chemotherapy and, at that time, are considered to have exhausted hormone therapy options.

Read more [about trial](#).

SSA/17/QGC/310

Principal Investigator: Dr Marcin Dzienis

Lead Contact: Mr Jacob Darch

Phone: (07) 5687 2712

Email: Jacob.Darch@health.qld.gov.au

Radiation Oncology

We treat patients' cancer through radiation therapy to reduce or remove symptoms.

TROG 14.04 HART trial

Active, recruiting patients

This trial assesses the feasibility of Deep Inhalation Breath Hold (DIBH) to reduce cardiac toxicity in patients with left-sided breast cancer undergoing radiotherapy.

Read more [about trial](#).

SSA/17/QGC/291

Principal Investigator: Dr Dominic Lunn

Lead Contact: Ms Danielle Miller

Phone: (07) 5687 2363

Email: MillerD@roc.team

NOX66-002A trial

Active, recruiting patients

This study investigates using NOX66 and radiation therapy treatment for patients with metastatic castrate-resistant prostate cancer (CRPC) who are undergoing palliative radiotherapy for pain and symptom management.

Read more [about trial](#).

SSA/17/QGC/376

Principal Investigator: Dr James Jackson

Lead Contact: Ms Danielle Miller

Phone: (07) 5687 2363

Email: MillerD@roc.team

ENZARAD trial

Active, recruiting patients

This Phase 3 study compares the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or with currently available anti-androgen drugs in prostate cancer treatment.

Read more [about trial](#).

SSA/16/QGC/138

Principal Investigator: Dr James Jackson

Lead Contact: Ms Danielle Miller

Phone: (07) 5687 2363

Email: MillerD@roc.team

PEARL trial

Active, recruiting patients

This study determines whether early referral in palliative care improves quality of life, overall survival and health care resource use in patients with recently diagnosed, advanced thoracic malignancies.

Read more [about trial](#).

SSA/17/QGC/226

Principal Investigator: Dr Peter Gorayski

Lead Contact: Ms Danielle Miller

Phone: (07) 5687 2363

Email: MillerD@roc.team

Complementary medicines

Complementary medicines, which can also be called alternative medicines, involve various supplements such as vitamin or herbal products.

Probiotic and shift work study trial

Active, recruiting patients

A study moderating the effects of sleep disruption/deprivation on gut health and the immune system with probiotics.

Read more [about trial](#).

SSA/17/QGC/346

Principal Investigator: Professor Allan Cripps

Lead Contact: Ms Rebecca Rarnsey

Phone: 0422 381 424

Email: Probiotic-study@griffith.edu.au

Emergency medicine

We deal with medicines for patients who need urgent healthcare attention.

SIT intervention trial

Active, recruiting patients

This study compares psychotherapy and exercise versus standard physiotherapy alone to treat individuals with a recent whiplash injury.

Read more [about trial](#).

SSA/15/QGC/122

Lead Contact: Dr Gerben Keijzers

Phone: (07) 5687 5274

Email: Gerben.Keijzers@health.qld.gov.au

REFRESH trial

Active, participant follow-up only

This is a randomised trial of restricted fluid resuscitation in patients with sepsis-associated hypotension.

Read more [about trial](#).

SSA/15/QGC/317

Lead Contact: Dr Gerben Keijzers

Phone: (07) 5687 5274

Email: Gerben.Keijzers@health.qld.gov.au

Pregabalin for acute whiplash trial

Active, recruiting patients

This is a Phase 3 trial of pregabalin vs placebo in targeting pro-nociceptive mechanisms to prevent chronic pain after whiplash injury in at-risk individuals.

Read more [about trial](#).

SSA/16/QGC/348

Lead Contact: Dr Gerben Keijzers

Phone: (07) 5687 5274

Email: Gerben.Keijzers@health.qld.gov.au

Intensive Care

We treat patients with severe illnesses and life threatening injuries to provide constant close monitoring of their condition.

Bling III trial

Active, recruiting patients

This Phase 3 study determines whether patients receiving beta-lactam antibiotics through various administration methods have a better chance of recovering from their illness.

Read more [about trial](#).

SSA/18/QGC/94

Principal Investigator: Dr James Winearls

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

EPO TBI trial

Active, recruiting patients

This Phase 3 study determines if erythropoietin (EPO) reduces secondary brain injury and helps patients make a better recovery after a traumatic brain injury.

Read more [about trial](#).

SSA/18/QGC/54

Principal Investigator: Dr James Winearls

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

WEAN SAFE trial

Active, participant follow-up only

This observational study assesses the management and spectrum of approaches to weaning from ventilation in patients requiring invasive mechanical ventilation for any reason or over a minimum 24-hour period.

Read more [about trial](#).

SSA/18/QGC/9

Principal Investigator: Dr James McCullough

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

PROMOTE-SAH trial

Active, recruiting patients

This is an observational study of aneurysmal subarachnoid haemorrhage (aSAH) cases to explore the number of admissions and variations of patient management in intensive care units in Australia and New Zealand.

Read more [about trial](#).

SSA/17/QGC/34

Principal Investigator: Dr David Pearson

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

The TAME Cardiac Arrest trial

Active, recruiting patients

This Phase 3 trial determines the ability of higher carbon dioxide (CO₂) levels to reduce brain damage compared to giving patients 'normal' to 'slightly higher than normal' blood CO₂ levels and assessing their ability to return to normal life-tasks.

Read more [about trial](#).

HREC/17/AUSTIN/209

Principal Investigator: Dr James Winerals & Dr Angelly Martinez

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

PLUS trial

Active, recruiting patients

This trial determines whether fluid resuscitation and intravenous fluid therapy with a “balanced” crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline).

Read more [about trial](#).

SSA/17/QGC/85

Principal Investigator: Dr Yi-Chung Bong

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

ECMO Point Prevalence Study

Active, recruiting patients

This study identifies the prevalence of paediatric and adult cannula site infection, bloodstream infections, or other nosocomial infections associated with cannula dressings and securement practice in patients receiving extracorporeal membrane oxygenation (ECMO).

Read more [about trial](#).

SSA/17/QGC/287

Principal Investigator: Dr James Winerals

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

TBI CORTISOL trial

Active, recruiting patients

This study compares total and free plasma cortisol response to the short synacthen test in patients with severe traumatic brain injury.

Read more [about trial](#).

SSA/14/QGC/165

Principal Investigator: Dr James Winerals

Lead Contact: Ms Mandy Tallott

Phone: (07) 5687 5678

Email: Mandy.Tallott@health.qld.gov.au

The IMPACT trial

Active, recruiting patients

This study aims to improve families' satisfaction with care and capacity to act as agents of best practice, which will translate into better patient and family outcomes.

Read more [about trial](#).

SSA/17/QGC/54

Principal Investigator: Dr Andrea Marshall

Lead Contact: Ms Georgia Tobiano

Phone: (07) 5687 3256

Email: Georgia.Tobiano@health.qld.gov.au

Medical Specialities and Medical Imaging

Cardiology

We diagnose and treat heart disease, and parts of the circulatory system.

STRENGTH trial

Active, participant follow-up only

This Phase 3 trial uses EpaNova® (omega-3s) with cholesterol lowering medications to reduce major cardiac events.

Read more [about trial](#).

SSA/15/QGC/168

Principal Investigator: Prof Laurie Howes

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

SPHInX trial

Active, recruiting patients

This is a trial of a new treatment for scleroderma-related pulmonary arterial hypertension to determine if any health benefits are gained from adding apixaban (blood-thinning medication) to current therapy.

Read more [about trial](#).

SSA/15/QGC/195

Principal Investigator: Dr Greg Aroney

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

CAAN-AF trial

Active, recruiting patients

This trial determines if ablating the atrioventricular node, which controls electrical conduction from the heart's atria (top chamber) to its ventricles (lower chambers), will improve survival and heart failure symptoms in patients with co-existent atrial fibrillation (AF) that are receiving cardiac resynchronization therapy (CRT).

Read more [about trial](#).

SSA/17/QGC/132

Principal Investigator: Dr Robert Park

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

COPS trial

Active, recruiting patients

This Phase 3 trial determines if adding low-dose colchicine to current medical treatment improves outcomes after a heart attack.

Read more [about trial](#).

SSA/17/QGC/363

Principal Investigator: Prof Laurie Howes

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

COCOMO-ACS trial

Active, recruiting patients

This is a Phase 2 trial of colchicine vs placebo to prevent or reduce coronary plaque in patients with acute coronary syndromes.

Read more [about trial](#).

SSA/18/QGC/75

Principal Investigator: Dr Kuljit Singh

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

PROTECT-ICD trial

Active, recruiting patients

This is a trial for the early insertion of implantable cardioverter-defibrillators (ICD) after a heart attack when heart failure is present.

Read more [about trial](#).

SSA/16/QGC/264

Principal Investigator: Dr Robert Park

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

EMPEROR trial

Active, recruiting patients

This Phase 3 trial evaluates the safety and efficacy of empagliflozin vs placebo in patients with heart failure and preserved ejection fraction.

Read more [about trial](#).

SSA/18/QGC/84

Principal Investigator: Prof Laurie Howes

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

PARAGON trial

Active, participant follow-up only

This Phase 3 study evaluates the effects of LCZ696 compared to valsartan to improve cardiac outcomes in patients with heart failure and preserved ejection fraction.

Read more [about trial](#).

SSA/15/QGC/43

Principal Investigator: Prof Laurie Howes

Lead Contact: Ms Tracey Brumby

Phone: (07) 5687 4952

Email: gchcardiologyresearch@health.qld.gov.au

Endocrinology

We care for and treat people with diseases caused by problems with their hormones and glands (endocrine system).

RAINBOW-T1D TRIAL

Active, recruiting patients

This Phase 2 study evaluates the safety and efficacy of GNbAC1, a monoclonal antibody, in patients with Type 1 diabetes.

Read more [about trial](#).

SSA/17/QGC/176

Principal Investigator: Dr Peter Davoren

Lead Contact: Ms Rachael Dunning

Phone: (07) 5687 4550

Email: DEMSResearch@health.qld.gov.au

Interventional Neuroradiology

We provide minimally invasive treatment and diagnostic imaging for a wide range of conditions involving the brain, the head and neck regions, and the spine and spinal cord.

SHIELD Trial

Active, participant follow-up only

This post marketing device trial assesses the performance of the Pipeline™ Flex Embolization Device with Shield Technology™ in patients undergoing treatment for an intracranial aneurysm.

Read more [about trial](#).

SSA/16/QGC/23

Principal Investigator: Dr Hal Rice

Lead Contact: Ms Cheryl Rapier

Phone: (07) 5687 3603

Email: DEMSResearch@health.qld.gov.au

INSPIRE Product Surveillance Registry (PSR)

Active, recruiting patients

This post-marketing registry provides continuous evaluation and periodic safety reporting of the effectiveness of Medtronic Neurovascular products used to treat intracranial aneurysms.

Read more [about trial](#).

SSA/17/QGC/247

Principal Investigator: Dr Hal Rice

Lead Contact: Ms Cheryl Rapier

Phone: (07) 5687 3603

Email: DEMSResearch@health.qld.gov.au

Neurology

We diagnose, treat and care for conditions and diseases involving the central and peripheral nervous system, including diseases of the brain, spinal cord, nerves and muscles (such as strokes, epilepsy, headaches, Alzheimer's, multiple sclerosis, Parkinson's and various forms of pain).

IVIG-11-74 TRIAL

Active, recruiting patients

This Phase 4 post-marketing safety study evaluates the occurrence of aseptic meningitis syndrome (AMS) in adult patients receiving Intragam® 10 NF.

Read more [about trial](#).

SSA/17/QGC/20

Principal Investigator: Dr Arman Sabet

Lead Contact: Ms Helen McEvoy

Phone: (07) 5687 4553

Email: DEMSResearch@health.qld.gov.au

EMERALD TRIAL

Active, recruiting patients

This Phase 3 trial tests if cannabis based medicine extract (CannTrust CBD Oil) can slow the disease progression of Amyotrophic Lateral Sclerosis (ALS) or Motor Neurone Disease (MND) in patients with early stage ALS/MND.

SSA/18/QGC/153

Principal Investigator: Dr Arman Sabet

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSResearch@health.qld.gov.au

Extend IA TNK Part 2

Active, recruiting patients

This is a Phase 2 trial for patients presenting with an acute ischaemic stroke that are eligible for thrombolysis (clot busting drug) and thrombectomy (clot retrieval). Patients will be randomised to either 0.4mg/kg or 0.25mg/kg of intravenous tenecteplase before undergoing thrombectomy.

Read more [about trial](#).

SSA/15/QGC/241

Principal Investigator: Dr Peter Bailey

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSEResearch@health.qld.gov.au

TASTE Trial

Active, recruiting patients

This Phase 3 trial compares two clot dissolving medications tenecteplase and alteplase for stroke treatment to determine which will help more patients have less disability at 3 months following stroke.

Read more [about trial](#).

SSA/15/QGC/6

Principal Investigator: Dr Arman Sabet

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSEResearch@health.qld.gov.au

ATTUNE Trial

Active, recruiting patients

This is an MRI registry of clinical and radiological outcomes following the initiation of anticoagulation after ischaemic stroke or transient ischaemic attack in patients with atrial fibrillation.

Read more [about trial](#).

SSA/18/QGC/6

Principal Investigator: Dr Meng Tan

Lead Contact: Ms Cheryl Rapier

Phone: (07) 5687 3603

Email: DEMSResearch@health.qld.gov.au

INSPIRE Registry

Active, recruiting patients

This is an international web-based database collecting imaging and clinical stroke data to measure the implementation of advanced CT imaging in stroke.

Read more [about trial](#).

SSA/14/QGC/134

Principal Investigator: Dr Sandeep Bhuta

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSResearch@health.qld.gov.au

START-EXTEND Trial

Active, recruiting patients

This is a Phase 3 trial about extending the time for thrombolysis to 9 hours for patients diagnosed with an acute ischaemic stroke or after a 'wake up stroke'.

Read more [about trial](#).

SSA/16/QGC/81

Principal Investigator: Dr Arman Sabet

Lead Contact: Ms Cheryl Rapier

Phone: (07) 5687 3603

Email: DEMSResearch@health.qld.gov.au

TEMPO-2 Trial

Active, recruiting patients

This is a Phase 3 trial enrolling patients with atrial fibrillation that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Patients will be randomised to tenecteplase or standard of care. Patients will be assessed up to 90 days after the event to determine patient outcomes.

Read more [about trial](#).

SSA/17/QGC/374

Principal Investigator: Dr Sachin Mishra

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSResearch@health.qld.gov.au

THALES Trial

Active, recruiting patients

This Phase 3 trial investigates if the study drug ticagrelor and aspirin is more effective than placebo (inactive tablet) and aspirin in preventing new stroke events.

Read more [about trial](#).

SSA/18/QGC/10

Principal Investigator: Dr Arman Sabet

Lead Contact: Mr Berzenn Urbi

Phone: (07) 5687 4551

Email: DEMSResearch@health.qld.gov.au

Renal

We diagnose, treat and care for conditions and diseases of the kidneys and urinary tract.

CKD-FIX Trial

Active, participant follow-up only

This Phase 3 trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows the progression of chronic kidney disease (CKD).

Read more [about trial](#).

SSA/16/QGC/58

Principal Investigator: Dr Siddarth Sharma

Lead Contact: Ms Helen McEvoy

Phone: (07) 5687 4553

Email: DEMSResearch@health.qld.gov.au

Psychiatry

We specialise in diagnosing and preventing, through treatments such as psychotherapy and psychosocial care, various mental disorders.

CADENCE-M trial

Active, recruiting patients

This Phase 4 clinical trial determines if receiving an extract from the rind of the tropical fruit mangosteen, in addition to regular treatments, assists with the treatment of schizophrenia.

SSA/16/QGC/130

Read more [about trial](#).

Lead Contact: Dr Saveena Singh

Phone: (07) 5668 8600

Email: Saveena.Singh@health.qld.gov.au

KADS trial

Active, recruiting patients

This Phase 3 trial determines if a 4-week course of ketamine therapy administered subcutaneously is an effective therapy for treatment-resistant depression.

SSA/17/QGC/308

Read more [about trial](#).

Lead Contact: Dr Shanthi Sarma

Phone: (07) 5635 7098

Email: Shanthi.Sarma@health.qld.gov.au

CADENCE COMET trial

Active, recruiting patients

This Phase 4 clinical trial examines if starting diabetes medication called metformin at the same time as antipsychotic medication clozapine minimises the weight gain that can occur with clozapine treatment.

SSA/17/QGC/359

Read more [about trial](#).

Lead Contact: Dr Savio Sardinha

Phone: (07) 5635 7098

Email: Savio.Sardinha@health.qld.gov.au

Surgery

Breast Surgery

We are surgeons, who are skilled in operating on the breast performing tumor biopsies, removal surgery or breast reconstructions.

ROLLIS trial

Active, participant follow-up only

This trial investigates whether Radio-guided Occult Lesion Localisation using Iodine-125 Seeds (ROLLIS) to remove impalpable breast cancer can reduce the rate of subsequent oncological surgery when compared with standard hook-wire localisation.

Read more [about trial](#).

SSA/16/QGC/11

Principal Investigator: Dr Rhea Liang

Lead Contact: Ms Sue Black

Phone: (07) 5668 6000

Email: Rhea.Liang@health.qld.gov.au

MPH and Seroma Formation After Mastectomy trial

Active, recruiting patients

This trial investigates whether the use of microporous polysaccharide hemosphere (MPH®; blood clotting technology) reduces the rate of seroma formation in breast cancer patients following mastectomy.

Read more [about trial](#).

SSA/16/QGC/115

Principal Investigator: Dr Diana Tam

Lead Contact: Ms Sue Black

Phone: (07) 5668 6000

Email: Rhea.Liang@health.qld.gov.au

ENT Surgery

We are surgeons, who treat diseases revolving around the Ear, Nose, and Throat (ENT) region.

Use of Surgicel in Parotid Surgery trial

Active, recruiting patients

This study explores the use of Surgicel® (oxidised regenerated cellulose) in parotid (salivary gland) surgery and the incidence of post-operative complications, facial nerve function and length of hospital stay.

Read more [about trial](#).

SSA/16/QGC/298

Lead Contact: Dr Matthew Cronin

Phone: (07) 5687 0000

Email: Matthew.Cronin@health.qld.gov.au

Orthopaedic Surgery

We treat musculoskeletal conditions such as issues with your joints, bones, and muscles.

IFTT Trial

Active, recruiting patients

This trial determines if oral ibuprofen has a positive outcome in patients that have undergone flexor tendon repair of the hand.

Read more [about trial](#).

SSA/17/QGC/354

Lead Contact: Professor Randy Bindra

Phone: (07) 5687 0334

Email: Randy.Bindra@health.qld.gov.au

Colorectal Surgery

We treat diseases that involve the colon, rectum, or anus.

ADIPOSE trial

Active, recruiting patients

This Phase 3 trial determines if including a Very Low Energy Diet (VLED) in the preoperative phase before laparoscopic rectal resection for rectal cancer in obese patients improves short-term clinical outcomes.

Read more [about trial](#).

SSA/16/QGC/325

Lead Contact: A/Professor Michael Von Papen

Phone: (07) 5687 3240

Email: Michael.VonPapen@health.qld.gov.au

Anaesthetics

We anaesthetise (reduce consciousness), sedate, and provide pain relief for patients.

The PADDI trial

Active, recruiting patients

This trial examines the benefits and complications of administering a steroid drug (dexamethasone) to adult patients undergoing non-urgent surgical procedures who receive general anaesthesia.

Read more [about trial](#).

SSA/16/QGC/203

Lead Contact: Dr Paul Slocombe

Phone: (07) 5687 8626

Email: Paul.Slocombe@health.qld.gov.au

Endoscopy

We use an endoscope (an instrument with a camera attached) to examine areas within your body.

UGIB trial

Enrolling inpatients

This study compares two groups of patients: patients randomised to receive an early capsule endoscopy (non-invasive device) vs standard colonoscopies to detect bleeding sources in the small bowel and improve patient outcomes

Read more [about trial](#).

SSA/16/QGC/89

Lead Contact: Dr Sneha John

Phone: (07) 5687 0685

Email: Sneha.John@health.qld.gov.au

Trauma

We diagnose and treat patients who have had high-risk, life-threatening injuries such as motor vehicle accidents, serious falls, gunshot wounds or traumatic brain injuries.

FEISTY JUNIOR trial

Active, recruiting patients

This Phase 2 trial investigates using fibrinogen concentrate in children with severe traumatic haemorrhage.

Read more [about trial](#).

Principal Investigator: Dr Shane George

Lead Contact: Ms Elizabeth Wake

Phone: (07) 5678 4149

Email: Elizabeth.Wake@health.qld.gov.au

PATCH trial

Active, recruiting patients

A Phase 3 trial to determine whether giving severely injured adults a drug called tranexamic acid (TXA) as soon as possible after injury will improve their chances of survival and their level of recovery at six months.

Read more [about trial](#).

SSA/16/QGC/163

Principal Investigator: Dr Martin Wullschleger

Lead Contact: Ms Elizabeth Wake

Phone: (07) 5678 4149

Email: Elizabeth.Wake@health.qld.gov.au

POLAR trial

Active, participant follow-up only

A trial developed to investigate whether early cooling of patients with severe traumatic brain injury is associated with better outcomes.

Read more [about trial](#).

SSA/16/QGC/178

Principal Investigator: Dr Martin Wullschleger

Lead Contact: Ms Elizabeth Wake

Phone: (07) 5678 4149

Email: Elizabeth.Wake@health.qld.gov.au

PROPHIICY trial

Active, recruiting patients

A Queensland based, pre-hospital study identifying the incidence of injured patients at risk of bleeding to death when paramedics arrive to treat them.

Read more [about trial](#).

SSA/16/QGC/63

Principal Investigator: Dr Martin Wullschleger

Lead Contact: Ms Elizabeth Wake

Phone: (07) 5678 4149

Email: Elizabeth.Wake@health.qld.gov.au

Women, Children and Newborns

Obstetrics and Gynaecology

We care for and treat pregnant women, their unborn child and manage disorders and problems that are unique to the female reproductive organs.

The My Baby's Movements (MBM) trial

Active, recruiting eligible outpatients only

A study to raise pregnant women's knowledge and awareness of their baby's movement during pregnancy.

Read more [about trial](#).

SSA/15/QGC/269

Principal Investigator: Professor David Ellwood

Lead Contact: Ms Cheryl Bailey

Phone: 07 5678 0702

Email: D.Ellwood@griffith.edu.au

Paediatrics and Neonates

Paediatricians treat children or adolescents, while neonatologists treat newborns, who are often premature or sick.

Bell's Palsy In Children (BellPIC) trial

Active, recruiting patients

A Phase 3 study for children presenting to emergency departments with a recent onset of Bell's palsy to determine if treatment with prednisolone results in more children with recovery at 1 month compared to placebo.

Read more [about trial](#).

SSA/16/QGC/91

Principal Investigator: Dr Shane George

Lead Contact: Ms Joanna Cronin

Phone: (07) 5687 1275

Email: Shane.George@health.qld.gov.au

VICTOR trial

Active, recruiting patients

This is a Phase 2 trial to evaluate the antiviral effects of AK0529, an investigational antiviral agent, in infants hospitalized with a respiratory syncytial virus (RSV) infection.

Read more [about trial](#).

SSA/17/QGC/114

Principal Investigator: Dr Shane George

Lead Contact: Ms Richele Tucker

Phone: (07) 5687 1275

Email: Shane.George@health.qld.gov.au

PARIS II trial

Active, recruiting patients

A Phase 3 study to assess which children with common respiratory illnesses such as pneumonia, bronchitis and asthma benefit from nasal high flow therapy (NHF) compared to current best practice (standard oxygen delivery via subnasal cannula or facemask).

Read more [about trial](#).

SSA/17/QGC/135

Principal Investigator: Dr Shane George

Lead Contact: Ms Ricku Haataja

Phone: (07) 5687 1275

Email: Shane.George@health.qld.gov.au

RAPIDS trial

Active, recruiting patients

A study to investigate whether a novel blood test for genetic markers of sepsis can accurately identify infection severity and reduce the time to diagnose sepsis (a severe blood infection).

Read more [about trial](#).

SSA/18/QGC/5

Principal Investigator: Dr Shane George

Lead Contact: Ms Joanna Cronin

Phone: (07) 5687 1275

Email: Shane.George@health.qld.gov.au

KIDS THRIVE trial

Active, recruiting patients

A trial to assess the effectiveness of Trans-nasal Humidified Rapid- Insufflation Ventilatory Exchange in Children Requiring Emergent Intubation (KIDS THRIVE).

Read more [about trial](#).

SSA/17/QGC/13

Principal Investigator: Dr Shane George

Lead Contact: Ms Joanna Cronin

Phone: (07) 5687 1275

Email: Shane.George@health.qld.gov.au

GAME Trial

Active, recruiting patients

A trial to harness neuroplasticity in infants by comparing the GAME (Goals Activity Motor Enrichment) intervention versus standard practice to improve motor performance in infants at high risk of cerebral palsy.

Read more [about trial](#).

SSA/17/QGC/241

Lead Contact: Dr Peter Schmidt

Phone: (07) 5687 3510

Email: Peter.Schmidt@health.qld.gov.au